AVALO THERAPEUTICS, INC. Amortization of Intangible Assets
AVALO THERAPEUTICS, INC. (AVTX) reported Amortization of Intangible Assets of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2024-03-29
- AVALO THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2023-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2023-09-30 was $0.00.
- AVALO THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2023-06-30 was $0.00.
- AVALO THERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. amortization of intangible assets for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- AVALO THERAPEUTICS, INC. amortization of intangible assets for fiscal 2022 was $38.00K, a 97.54% decline from fiscal 2021.
- AVALO THERAPEUTICS, INC. amortization of intangible assets for fiscal 2021 was $1.55M, a 11.14% decline from fiscal 2020.
- AVALO THERAPEUTICS, INC. amortization of intangible assets for fiscal 2020 was $1.74M, a 30.02% increase from fiscal 2019.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 | ||||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 | ||||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 derived: sum of 4 quarters · filed 2024-03-29 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $38.00K 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $38.00K 10-Q · filed 2023-11-09 | $304.00K derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $38.00K 10-Q · filed 2023-08-03 | $304.00K derived: sum of 3 quarters · filed 2023-08-03 | $732.00K derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | $38.00K 10-Q · filed 2023-05-04 | $304.00K derived: sum of 2 quarters · filed 2023-05-04 | $732.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.16M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $266.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $694.00K derived: sum of 2 quarters · filed 2023-03-29 | $1.12M derived: sum of 3 quarters · filed 2023-03-29 | $1.55M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $428.00K 10-Q · filed 2022-11-07 | $856.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.28M 10-Q · filed 2022-11-07 | $1.78M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $428.00K 10-Q · filed 2022-08-04 | $853.00K 10-Q · filed 2022-08-04 | $1.35M derived: sum of 3 quarters · filed 2022-08-04 | $1.76M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $424.00K 10-Q · filed 2022-05-05 | $927.00K derived: sum of 2 quarters · filed 2022-05-05 | $1.33M derived: sum of 3 quarters · filed 2022-05-05 | $1.74M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $503.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $907.00K derived: sum of 2 quarters · filed 2022-03-02 | $1.31M derived: sum of 3 quarters · filed 2022-03-02 | $1.74M 10-K · filed 2022-03-02 | $1.74M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $404.00K 10-Q · filed 2021-11-09 | $403.50K 10-Q · filed 2020-11-09 | $808.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.24M 10-Q · filed 2021-11-09 | $1.24M 10-Q · filed 2020-11-09 | $1.57M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $404.00K 10-Q · filed 2021-08-02 | $403.50K 10-Q · filed 2020-08-06 | $834.00K 10-Q · filed 2021-08-02 | $834.08K 10-Q · filed 2020-08-06 | $1.17M derived: sum of 3 quarters · filed 2021-08-02 | $1.50M derived: sum of 4 quarters · filed 2021-08-02 | ||
| 2020-03-31 | $431.00K 10-Q · filed 2021-05-13 | $430.58K 10-Q · filed 2020-05-07 | $765.75K derived: sum of 2 quarters · filed 2021-05-13 | $1.10M derived: sum of 3 quarters · filed 2021-05-13 | $1.44M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $334.75K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $669.50K derived: sum of 2 quarters · filed 2021-03-08 | $1.00M derived: sum of 3 quarters · filed 2021-03-08 | $1.34M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $334.75K 10-Q · filed 2020-11-09 | $1.04M 10-Q · filed 2019-11-14 | $669.50K derived: sum of 2 quarters · filed 2020-11-09 | $1.00M 10-Q · filed 2020-11-09 | $3.20M 10-Q · filed 2019-11-14 | -$495.73K derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $334.75K 10-Q · filed 2020-08-06 | $1.08M 10-Q · filed 2019-08-08 | $669.50K 10-Q · filed 2020-08-06 | $2.16M 10-Q · filed 2019-08-08 | -$830.48K derived: sum of 3 quarters · filed 2020-08-06 | $234.92K derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | $334.75K 10-Q · filed 2020-05-07 | $1.08M 10-Q · filed 2019-05-09 | -$1.17M derived: sum of 2 quarters · filed 2020-05-07 | -$99.83K derived: sum of 3 quarters · filed 2020-05-07 | $1.13M derived: sum of 4 quarters · filed 2020-05-07 | |||
| 2018-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$434.57K derived: sum of 2 quarters · filed 2020-03-11 | $798.46K derived: sum of 3 quarters · filed 2020-03-11 | $1.82M 10-K · filed 2020-03-11 | $4.53M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $1.07M 10-Q · filed 2019-11-14 | $2.30M derived: sum of 2 quarters · filed 2019-11-14 | $3.32M 10-Q · filed 2019-11-14 | $3.72M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $1.23M 10-Q · filed 2019-08-08 | $2.25M 10-Q · filed 2019-08-08 | $2.65M derived: sum of 3 quarters · filed 2019-08-08 | $2.65M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $1.02M 10-Q · filed 2019-05-09 | $1.42M derived: sum of 2 quarters · filed 2019-05-09 | $1.42M derived: sum of 3 quarters · filed 2019-05-09 | $1.42M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $403.52K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $403.52K derived: sum of 2 quarters · filed 2019-03-18 | $403.52K derived: sum of 3 quarters · filed 2019-03-18 | $403.52K 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-13 | $0.00 derived: sum of 2 quarters · filed 2018-11-13 | $0.00 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-11 | |||||||
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |